Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-PanTumor01: Ifinatamab Deruxtecan in Advanced Solid Tumors
NCT04145622Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of ifinatamab deruxtecan in solid tumor (advanced stage) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting toxicities at 21 days, Adverse events and 1 more. Started Nov 2019; status: active, not recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04145622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145622.